검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | FU (5-Fluorouracil, 5-Fluorouracil (FU)) CSPC Ouyi Pharmaceutical Co., Ltd.·Colorectal Tumors ORR 72.7%·t½ 4.39 h |
|---|---|
Overview Program | 5-Fluorouracil (FU) |
Overview Company | CSPC Ouyi Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Tumors |
Overview Indication | Colorectal Tumors; Colorectal Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targets and key signaling pathway |
MoA Biomarker | biomarkers of environmentally driven viral carcinogenesis |
PK/PD Half-life | 4.39 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8 + T cell function via the FYN-PI3K/AKT axis.. Shengxian Decoction (SXD), a traditional Chinese herbal formula, has demonstrated significant clinical efficacy against lung adenocarcinoma (LUAD). However, its exact mechanisms of action remain to be elucidated. This study aimed to establish an animal model ca… |
Clinical Primary efficacy | ORR 72.7% |
Clinical ORR | 72.7% |
Clinical PFS | 10.41 |
Clinical OS | 19.7 |
Clinical Result source | ClinicalTrials.gov NCT04363801 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | FU (5-Fluorouracil, 5-Fluorouracil (FU)) CSPC Ouyi Pharmaceutical Co., Ltd.·Colorectal Tumors ORR 72.7%·t½ 4.39 h |
|---|---|
Overview Program | 5-Fluorouracil (FU) |
Overview Company | CSPC Ouyi Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Tumors |
Overview Indication | Colorectal Tumors; Colorectal Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targets and key signaling pathway |
MoA Biomarker | biomarkers of environmentally driven viral carcinogenesis |
PK/PD Half-life | 4.39 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Shengxian decoction suppresses malignant progression of lung adenocarcinoma by enhancing CD8 + T cell function via the FYN-PI3K/AKT axis.. Shengxian Decoction (SXD), a traditional Chinese herbal formula, has demonstrated significant clinical efficacy against lung adenocarcinoma (LUAD). However, its exact mechanisms of action remain to be elucidated. This study aimed to establish an animal model ca… |
Clinical Primary efficacy | ORR 72.7% |
Clinical ORR | 72.7% |
Clinical PFS | 10.41 |
Clinical OS | 19.7 |
Clinical Result source | ClinicalTrials.gov NCT04363801 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교